Mechanism of Action Data On PV-10 Demonstrates Therapy Induces Immunologic Response
- Leads to Regression of Untreated Lung and Cutaneous Melanoma Metastases -
- Results Detailed in Poster Presentation at the Society of Surgical Oncology Annual Meeting; Details of Poster Expected to Be Released Next Week -
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Mar 23, 2012 - Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical data on the immunologic mechanism of action of PV-10, presented at the Society of Surgical Oncology Annual Meeting, confirms that PV-10 chemoablation of melanoma lesions induces a systemic response that can lead to regression of synchronous lung metastases or synchronous subcutaneous melanoma. Details from the poster presentation are expected to be made available by Provectus next week.
The study was undertaken to elucidate the apparent systemic effect of PV-10 that has been observed in Phase 1 and Phase 2 clinical trials, leading to regression of untreated bystander lesions in some melanoma patients. The report of the nonclinical mechanism study's findings, entitled “Intralesional Injection of Melanoma with Rose Bengal Induces Regression of Untreated Synchronous Melanoma in a Murine Model,” was authored by P. Toomey, L. Martin, A. Mckay, A. Sarnaik and S. Pilon-Thomas of the H. Lee Moffitt Cancer Center & Research Institute. The abstract, #P265, was included in the Society of Surgical Oncology's 65th Annual Symposium Abstract Book. Additional data is being presented during the Annual Meeting's melanoma poster session on March 23 and 24, 2012. The abstract can be accessed at the following link:
Craig Dees, Ph.D., CEO of Provectus said, “The data from this independent study validates our belief that PV-10 induces systemic effects similar to those observed with immunotherapy or a vaccine. However, in contrast to conventional immunotherapies or vaccines, PV-10 also leads to a readily apparent and well-documented, rapid destruction of the treated lesions, which appears to afford a unique combination of reduced tumor burden and in situ immune stimulation against remaining tumor tissue. We are delighted about the abstract's report on regression of both synchronous metastases of the lung and subcutaneous melanoma, and look forward to providing further details on Dr. Toomey's work in the near future.”
About the Society of Surgical Oncology®
The Society of Surgical Oncology is the premier organization for surgeons and health care providers dedicated to advancing and promoting the science and treatment of cancer. The Society's focus on all solid-tumor disease sites is reflected in its Annual Cancer Symposium, monthly scientific journal (Annals of Surgical Oncology), special initiatives, and committee structure. For more information on the Annual Meeting, please go to: http://www.surgonc.org/meetings--events/annual-cancer-symposium.aspx
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Contact: Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, VP – Investor Relations
Bill Gordon, SVP – Media Relations
Posted: March 2012